Loading...
XNASRGC
Market cap63mUSD
Dec 27, Last price  
4.90USD
1D
-0.61%
1Q
-11.55%
IPO
-48.74%
Name

Regencell Bioscience Holdings Ltd

Chart & Performance

D1W1MN
XNAS:RGC chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
0.58%
Rev. gr., 5y
%
Revenues
0k
2,140,000,0002,489,000,0002,468,000,0002,598,000,0002,661,000,0002,771,000,0002,893,900,0002,807,900,0002,824,200,0003,038,100,0002,990,100,0003,127,300,0003,197,100,0003,163,000,000000000
Net income
-4m
L-26.73%
117,000,000185,000,00082,000,00086,000,000363,000,00072,000,00095,500,00077,600,000144,800,000157,700,000105,600,000153,400,000170,400,000112,300,000-390,990-812,371-1,346,745-7,422,728-5,871,130-4,301,837
CFO
-4m
L-19.37%
373,000,000476,000,000387,000,000304,000,000800,000,000270,000,000410,800,000259,400,000346,600,000346,900,000349,100,000434,400,000410,500,000409,900,000-390,990-726,573-767,311-5,267,055-4,962,949-4,001,687
Dividend
Feb 15, 20180.22 USD/sh

Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
URL
https://www.regencellbioscience.com/
IPO date
Jul 16, 2021
Employees
13
Domiciled in
HK
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062017‑122016‑122015‑122015‑00
Income
Revenues
Cost of revenue
1,812
7,043
8,222
Unusual Expense (Income)
NOPBT
(1,812)
(7,043)
(8,222)
NOPBT Margin
Operating Taxes
312
(191)
(172)
Tax Rate
NOPAT
(2,124)
(6,852)
(8,050)
Net income
(4,302)
-26.73%
(5,871)
-20.90%
(7,423)
451.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
22,673
BB yield
-5.04%
Debt
Debt current
60
438
411
Long-term debt
112
489
1,132
Deferred revenue
Other long-term liabilities
Net debt
(7,790)
(10,637)
(14,874)
Cash flow
Cash from operating activities
(4,002)
(4,963)
(5,267)
CAPEX
(5)
(27)
(781)
Cash from investing activities
5,243
59
(10,781)
Cash from financing activities
102
135
22,406
FCF
(1,478)
(6,284)
(10,017)
Balance
Cash
7,961
11,565
16,417
Long term investments
Excess cash
7,961
11,565
16,417
Stockholders' equity
(21,663)
(17,442)
(11,428)
Invested Capital
29,967
29,896
29,281
ROIC
ROCE
EV
Common stock shares outstanding
13,013
13,013
13,013
Price
3.36
-85.42%
23.04
-33.42%
34.61
 
Market cap
43,723
-85.42%
299,816
-33.42%
450,310
 
EV
35,933
289,138
435,451
EBITDA
(1,066)
(6,274)
(7,618)
EV/EBITDA
Interest
23
Interest/NOPBT